Invention Grant
![Crystalline form of the compound (s)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol](/docs/US/2023-12-05/US11834443B2/abs.jpg.600x600.jpg)
- Patent Title: Crystalline form of the compound (s)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol
-
Application No.: US17810545Application Date: 2022-07-01
-
Publication No.: US11834443B2Publication Date: 2023-12-05
- Inventor: Cyrille Lescop , Jasper Dingemanse , Andreas Krause
- Applicant: Idorsia Pharmaceuticals Ltd
- Applicant Address: CH Allschwil
- Assignee: Idorsia Pharmaceuticals Ltd
- Current Assignee: Idorsia Pharmaceuticals Ltd
- Current Assignee Address: CH Allschwil
- Agency: Hoxie & Associates LLC
- Priority: WO TEP2015061153 2015.05.20
- Main IPC: C07D413/04
- IPC: C07D413/04 ; A61P37/00 ; A61K31/047 ; A61K31/4245 ; A61K31/44 ; G01N23/20
![Crystalline form of the compound (s)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol](/abs-image/US/2023/12/05/US11834443B2/abs.jpg.150x150.jpg)
Abstract:
The present invention relates to a crystalline form of the compound (S)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol.
Public/Granted literature
Information query
